Neil Kumar, BridgeBio CEO at BIO22 (J.T. MacMillan Photography for Endpoints News)
July 17, 2023 07:00 AM EDTUpdated 09:41 AM
R&D

Bridge­Bio's AT­TR-CM tri­al odyssey ends with a win, show­ing pos­i­tive mor­tal­i­ty and hos­pi­tal­iza­tion da­ta

Drew Armstrong

Executive Editor

Bridge­Bio’s long wait for the fi­nal re­sults of its Phase III tri­al of aco­ramidis is over.

On Mon­day, the biotech said the 30-month read­out of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Sage re­ports Phase 2 fail­ure in Hunt­ing­ton's dis­ease, ends drug's de­vel­op­ment

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

Pfiz­er taps on­col­o­gy head Boshoff as Dol­sten's chief sci­en­tif­ic of­fi­cer suc­ces­sor

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Ex­clu­sive: For­mer Pfiz­er com­mer­cial chief An­gela Hwang to join Flag­ship

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times